Table 2. Pooled HRs for overall survival and subgroup analysis of B7-H3 expression in cancer patients.
| No. of study | No. of patients | Random effects model | Heterogeneity | PD value | P value | |||
|---|---|---|---|---|---|---|---|---|
| Pooled HR | 95%CI | P value | I2 | |||||
| OS | 26 | 3690 | 1.58 | 1.32–1.90 | 0.005 | 47.1% | < 0.00001 | |
| Ethnicity | 0.08 | |||||||
| Caucasian | 5 | 1309 | 1.18 | 0.84–1.66 | 0.264 | 23.5% | 0.350 | |
| Asian | 21 | 2381 | 1.67 | 1.38–2.04 | 0.015 | 44.5% | < 0.00001 | |
| Tumor type | 0.16 | |||||||
| Lung | 5 | 656 | 1.94 | 1.31–2.87 | 0.009 | 70.3% | 0.001 | |
| Pancreatic | 3 | 176 | 1.38 | 0.74–2.55 | 0.449 | 0 | 0.309 | |
| Gastric | 2 | 197 | 0.80 | 0.19–3.36 | 0.007 | 86.2% | 0.759 | |
| Colorectal | 3 | 933 | 1.02 | 0.71–1.47 | 0.559 | 0 | 0.901 | |
| Esophageal | 3 | 340 | 2.07 | 1.19–3.59 | 0.112 | 54.4% | 0.010 | |
| Other | 10 | 1388 | 1.53 | 1.18–1.99 | 0.284 | 17.3% | 0.001 | |
| Source of HR | 0.06 | |||||||
| Reported | 13 | 1780 | 1.80 | 1.37–2.36 | 0.0003 | 66.5% | < 0.0001 | |
| SC | 13 | 1910 | 1.29 | 1.05–1.59 | 0.729 | 0 | 0.014 | |
OS: Overall survival; PFS: progression-free survival; RFS: recurrence-free survival; HR: hazard ratio; CI: confidence interval; PD: P value for subgroup difference; SC: survival curve.